Last reviewed · How we verify
NCT07014540
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
Phase 4 trial testing Irinotecan Hydrochloride Liposome Injection in Neuroendocrine Carcinomas (NEC) in 45 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Beijing GoBroad Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 20 June 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Irinotecan Hydrochloride Liposome Injection
- 5-FU (5-fu) — full drug profile →
- LV — full drug profile →
Conditions studied
- Neuroendocrine Carcinomas (NEC) — all drugs for Neuroendocrine Carcinomas (NEC) →
Sponsor
Beijing GoBroad Hospital
Who can join
18 and older, any sex, with Neuroendocrine Carcinomas (NEC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the efficacy and safety of irinotecan liposome injection combined with 5-FU/LV in the treatment of advanced neuroendocrine carcinoma (NEC)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07014540
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Irinotecan Hydrochloride Liposome Injection
Trials testing the same drug.
- NCT06499610 — Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer · Phase 4 · not yet recruiting
- NCT06340204 — Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma · Phase 1 · recruiting
Other recruiting trials for Neuroendocrine Carcinomas (NEC)
Currently open trials in the same condition.
- NCT06893783 — Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients · Phase 2 · recruiting
Other Beijing GoBroad Hospital trials
Trials by the same sponsor.
- NCT07520357 — A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinom · Phase 2 · not yet recruiting
- NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
- NCT06326008 — Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri · Phase 1 · recruiting
- NCT07242417 — TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07179484 — To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07014540 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing GoBroad Hospital
- Last refreshed: 11 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07014540.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing